Atea Pharmaceuticals Inc. (AVIR) is advancing late-stage antiviral programs, led by its Phase 3 hepatitis C trials of Bemnifosbuvir and Ruzasvir. With enrollment completed in the pivotal C-BEYOND study and topline results expected in 2026, the company is positioning itself to deliver shorter, more tolerable treatment options.
Backed by a solid cash position and a growing pipeline that now includes hepatitis E candidates, Atea continues to attract market attention ahead of critical trial data.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.